These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 16953261

  • 1. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
    Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P.
    Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 3. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 4. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.
    Bryson A, de la Motte S, Dunk C.
    Br J Clin Pharmacol; 2009 Mar; 67(3):309-15. PubMed ID: 19220279
    [Abstract] [Full Text] [Related]

  • 5. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
    Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, Finer N, Rössner S, Lawrence E, Fletcher C, McCamish M, Author Group.
    Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
    [Abstract] [Full Text] [Related]

  • 6. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 7. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 8. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA.
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [Abstract] [Full Text] [Related]

  • 9. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 10. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Häeussler J, Guerciolini R, Showalter R, Everson GT.
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [Abstract] [Full Text] [Related]

  • 11. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.
    Med Pregl; 1999 Jun; 52(9-10):323-33. PubMed ID: 10624380
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Bays H, Rhyne J, Stein E, Rotenberg K, Doyle R.
    Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
    [Abstract] [Full Text] [Related]

  • 13. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.
    Gadde KM, Yonish GM, Wagner HR, Foust MS, Allison DB.
    Int J Obes (Lond); 2006 Jul; 30(7):1138-42. PubMed ID: 16418753
    [Abstract] [Full Text] [Related]

  • 14. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
    Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KR.
    Obes Res; 2001 Sep; 9(9):544-51. PubMed ID: 11557835
    [Abstract] [Full Text] [Related]

  • 15. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group.
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [Abstract] [Full Text] [Related]

  • 16. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A.
    Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
    [Abstract] [Full Text] [Related]

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 18. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 20. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.